Top Markets
Coin of the day
Adagio Therapeutics, Inc. Adagio Therapeutics, Inc.

Adagio Therapeutics, Inc.

ADGI
Classificação em ações #16435
Adagio Therapeutics, Inc. is a clinical-stage biopharmaceutical firm, primarily... Adagio Therapeutics, Inc. is a clinical-stage biopharmaceutical firm, primarily focused on the discovery, development, and subsequent commercialization of antibody-based therapeutics designed to combat infectious diseases across the United States. Its most advanced product candidate, ADG20 (adintrevimab), is a neutralizing antibody currently undergoing Phase 3 clinical trials. This antibody is being evaluated for both the treatment and prevention of coronavirus disease. Adagio Therapeutics also engages in strategic collaborations. It partners with Adimab, LLC to facilitate the discovery and optimization of novel proprietary antibodies. Furthermore, the company works with the Scripps Research Institute on research initiatives aimed at identifying vaccine candidates that could prevent, diagnose, or treat influenza and beta coronaviruses. Founded in 2020, Adagio Therapeutics maintains its headquarters in Waltham, Massachusetts.
Preço da ação
$4.64
Última sincronização: 2022-09-12
Valor de mercado
$293.43M
Variação (1 dia)
0.87%
Variação (1 ano)
0.00%
País
US
Negociar Adagio Therapeutics, Inc. (ADGI)

Categoria

Rácio P/S de Adagio Therapeutics, Inc. (ADGI)
Rácio P/S em 2026 TTM: 0
De acordo com os relatórios financeiros mais recentes e o preço das ações da Adagio Therapeutics, Inc., o rácio P/S atual (TTM) é 0. No final de 2026, o rácio P/S era 0.
Histórico do rácio P/S da Adagio Therapeutics, Inc. de 2026 a 2026
Rácio P/S no final de cada ano
Ano Rácio P/S Alterar
Não há dados suficientes para as datas fornecidas.
Rácio P/S de empresas semelhantes ou concorrentes
Empresa Rácio P/S Diferença do rácio P/S País
10.95 -
US
12.19 -
NL
24.99 -
US
3.75 -
AU
- -
CH